| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Departments of Cancer Biology [C. J. B., C. C. S., M. T. H., S. O., R. T., D. F., R. R., I. J. F.] and Gastrointestinal Oncology and Digestive Diseases [J. A.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and Novartis Pharma, CH-4002 Basel, Switzerland [P. T., E. B.]
We determined whether down-regulation of the epidermal growth factor-receptor (EGF-R) signaling pathway by oral administration of a novel EGF-R tyrosine kinase inhibitor (PKI166) alone or in combination with gemcitabine (administered i.p.) can inhibit growth and metastasis of human pancreatic carcinoma cells implanted into the pancreas of nude mice. Therapy beginning 7 days after orthotopic injection of L3.6pl human pancreatic cancer cells reduced the volume of pancreatic tumors by 59% in mice treated with gemcitabine only, by 45% in those treated with PKI166 only, and by 85% in those given both drugs. The combination therapy also significantly inhibited lymph node and liver metastasis, which led to a significant increase in overall survival. EGF-R activation was significantly blocked by therapy with PKI166 and was associated with significant reduction in tumor cell production of VEGF and IL-8, which in turn correlated with a significant decrease in microvessel density and an increase in apoptotic endothelial cells. Collectively, our results demonstrate that oral administration of an EGF-R tyrosine kinase inhibitor decreased growth and metastasis of human pancreatic cancer growing orthotopically in nude mice and increased survival. The therapeutic effects were mediated in part by inhibition of tumor-induced angiogenesis attributable to a decrease in production of proangiogenic molecules by tumor cells and increased apoptosis of tumor-associated endothelial cells.
This article has been cited by other articles:
|
|
 |
|
  A. Kleespies, I. Ischenko, M. E. Eichhorn, H. Seeliger, C. Amendt, O. Mantell, K.-W. Jauch, and C. J. Bruns Matuzumab Short-Term Therapy in Experimental Pancreatic Cancer: Prolonged Antitumor Activity in Combination with Gemcitabine Clin. Cancer Res., September 1, 2008; 14(17): 5426 - 5436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bianco, R. Rosa, V. Damiano, G. Daniele, T. Gelardi, S. Garofalo, V. Tarallo, S. De Falco, D. Melisi, R. Benelli, et al. Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells Clin. Cancer Res., August 15, 2008; 14(16): 5069 - 5080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Croyle, N. Akeno, J. A. Knauf, D. Fabbro, X. Chen, J. E. Baumgartner, H. A. Lane, and J. A. Fagin RET/PTC-Induced Cell Growth Is Mediated in Part by Epidermal Growth Factor Receptor (EGFR) Activation: Evidence for Molecular and Functional Interactions between RET and EGFR Cancer Res., June 1, 2008; 68(11): 4183 - 4191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Normanno and A. De Luca Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target? J. Clin. Oncol., December 20, 2007; 25(36): 5836 - 5837. [Full Text] [PDF]
|
|
|
|
|
|
T. Shimamura, R. E. Royal, M. Kioi, A. Nakajima, S. R. Husain, and R. K. Puri Interleukin-4 Cytotoxin Therapy Synergizes with Gemcitabine in a Mouse Model of Pancreatic Ductal Adenocarcinoma Cancer Res., October 15, 2007; 67(20): 9903 - 9912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-W. Lo, S.-C. Hsu, W. Xia, X. Cao, J.-Y. Shih, Y. Wei, J. L. Abbruzzese, G. N. Hortobagyi, and M.-C. Hung Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression Cancer Res., October 1, 2007; 67(19): 9066 - 9076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Lange, M. Kammerer, M. E. Hegi, S. Grotegut, A. Dittmann, W. Huang, E. Fluri, G. W. Yip, M. Gotte, C. Ruiz, et al. Endothelin Receptor Type B Counteracts Tenascin-C-Induced Endothelin Receptor Type A-Dependent Focal Adhesion and Actin Stress Fiber Disorganization Cancer Res., July 1, 2007; 67(13): 6163 - 6173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Moore, D. Goldstein, J. Hamm, A. Figer, J. R. Hecht, S. Gallinger, H. J. Au, P. Murawa, D. Walde, R. A. Wolff, et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., May 20, 2007; 25(15): 1960 - 1966. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zhang, J. A.F. Hannay, J. Liu, P. Das, M. Zhan, T. Nguyen, D. J. Hicklin, D. Yu, R. E. Pollock, and D. Lev Vascular Endothelial Growth Factor Overexpression by Soft Tissue Sarcoma Cells: Implications for Tumor Growth, Metastasis, and Chemoresistance. Cancer Res., September 1, 2006; 66(17): 8770 - 8778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. V. Heymach, M. Nilsson, G. Blumenschein, V. Papadimitrakopoulou, and R. Herbst Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4441s - 4445s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Adjei Novel combinations based on epidermal growth factor receptor inhibition. Clin. Cancer Res., July 15, 2006; 12(14): 4446s - 4450s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Younes, Y. D. Yazici, S. Kim, S. A. Jasser, A. K. El-Naggar, and J. N. Myers Dual Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor Inhibition with NVP-AEE788 for the Treatment of Aggressive Follicular Thyroid Cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3425 - 3434. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Camp, A. Yang, W. Liu, F. Fan, R. Somcio, D. J. Hicklin, and L. M. Ellis Roles of Nitric Oxide Synthase Inhibition and Vascular Endothelial Growth Factor Receptor-2 Inhibition on Vascular Morphology and Function in an In vivo Model of Pancreatic Cancer Clin. Cancer Res., April 15, 2006; 12(8): 2628 - 2633. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. L. Gable, B. A. Maddux, C. Penaranda, M. Zavodovskaya, M. J. Campbell, M. Lobo, L. Robinson, S. Schow, J. A. Kerner, I. D. Goldfine, et al. Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth. Mol. Cancer Ther., April 1, 2006; 5(4): 1079 - 1086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Yoon, S. H. Kim, M. Gonen, N. M. Heffernan, K. Y. Detwiller, W. R. Jarnagin, M. D'Angelica, L. H. Blumgart, K. K. Tanabe, and R. P. DeMatteo Profile of Plasma Angiogenic Factors Before and After Hepatectomy for Colorectal Cancer Liver Metastases Ann. Surg. Oncol., March 1, 2006; 13(3): 353 - 362. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Trevino, J. M. Summy, D. P. Lesslie, N. U. Parikh, D. S. Hong, F. Y. Lee, N. J. Donato, J. L. Abbruzzese, C. H. Baker, and G. E. Gallick Inhibition of Src Expression and Activity Inhibits Tumor Progression and Metastasis of Human Pancreatic Adenocarcinoma Cells in an Orthotopic Nude Mouse Model Am. J. Pathol., March 1, 2006; 168(3): 962 - 972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yano, H. Muguruma, Y. Matsumori, H. Goto, E. Nakataki, N. Edakuni, H. Tomimoto, S. Kakiuchi, A. Yamamoto, H. Uehara, et al. Antitumor Vascular Strategy for Controlling Experimental Metastatic Spread of Human Small-Cell Lung Cancer Cells with ZD6474 in Natural Killer Cell-Depleted Severe Combined Immunodeficient Mice Clin. Cancer Res., December 15, 2005; 11(24): 8789 - 8798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bozec, P. Formento, J. Ciccolini, R. Fanciullino, L. Padovani, X. Murraciole, J.-L. Fischel, and G. Milano Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation Mol. Cancer Ther., December 1, 2005; 4(12): 1962 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Trevino, J. M. Summy, M. J. Gray, M. B. Nilsson, D. P. Lesslie, C. H. Baker, and G. E. Gallick Expression and Activity of Src Regulate Interleukin-8 Expression in Pancreatic Adenocarcinoma Cells: Implications for Angiogenesis Cancer Res., August 15, 2005; 65(16): 7214 - 7222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Holden, S. G. Eckhardt, R. Basser, R. de Boer, D. Rischin, M. Green, M. A. Rosenthal, C. Wheeler, A. Barge, and H. I. Hurwitz Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors Ann. Onc., August 1, 2005; 16(8): 1391 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sini, L. Wyder, C. Schnell, T. O'Reilly, A. Littlewood, R. Brandt, N. E. Hynes, and J. Wood The Antitumor and Antiangiogenic Activity of Vascular Endothelial Growth Factor Receptor Inhibition Is Potentiated by ErbB1 Blockade Clin. Cancer Res., June 15, 2005; 11(12): 4521 - 4532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al. Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation Cancer Res., June 1, 2005; 65(11): 4716 - 4727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, S. Banerjee, Z.-w. Wang, D. J. Marciniak, A. P.N. Majumdar, and F. H. Sarkar Epidermal Growth Factor Receptor-Related Protein Inhibits Cell Growth and Induces Apoptosis of BxPC3 Pancreatic Cancer Cells Cancer Res., May 1, 2005; 65(9): 3877 - 3882. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kim, B. A. Schiff, O. G. Yigitbasi, D. Doan, S. A. Jasser, B. N. Bekele, M. Mandal, and J. N. Myers Targeted molecular therapy of anaplastic thyroid carcinoma with AEE788 Mol. Cancer Ther., April 1, 2005; 4(4): 632 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Schneider and K. D. Miller Angiogenesis of Breast Cancer J. Clin. Oncol., March 10, 2005; 23(8): 1782 - 1790. [Full Text] [PDF]
|
|
|
|
|
|
Y. W. Park, M. N. Younes, S. A. Jasser, O. G. Yigitbasi, G. Zhou, C. D. Bucana, B. N. Bekele, and J. N. Myers AEE788, a Dual Tyrosine Kinase Receptor Inhibitor, Induces Endothelial Cell Apoptosis in Human Cutaneous Squamous Cell Carcinoma Xenografts in Nude Mice Clin. Cancer Res., March 1, 2005; 11(5): 1963 - 1973. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tuccillo, M. Romano, T. Troiani, E. Martinelli, F. Morgillo, F. De Vita, R. Bianco, G. Fontanini, R. A. Bianco, G. Tortora, et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor-2 and Epidermal Growth Factor Receptor Small Molecule Tyrosine Kinase Inhibitor, in Combination with SC-236, a Cyclooxygenase-2 Inhibitor Clin. Cancer Res., February 1, 2005; 11(3): 1268 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Davis, R. Takamori, C. P. Raut, H. Q. Xiong, R. S. Herbst, W. M. Stadler, J. V. Heymach, G. D. Demetri, A. Rashid, Y. Shen, et al. Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668 Clin. Cancer Res., January 15, 2005; 11(2): 678 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Lev, S. J. Kim, A. Onn, V. Stone, D.-H. Nam, S. Yazici, I. J. Fidler, and J. E. Price Inhibition of Platelet-Derived Growth Factor Receptor Signaling Restricts the Growth of Human Breast Cancer in the Bone of Nude Mice Clin. Cancer Res., January 1, 2005; 11(1): 306 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Onn, T. Isobe, W. Wu, S. Itasaka, T. Shintani, K. Shibuya, Y. Kenji, M. S. O'Reilly, I. J. Fidler, and R. S. Herbst Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Does Not Improve Paclitaxel Effect in an Orthotopic Mouse Model of Lung Cancer Clin. Cancer Res., December 15, 2004; 10(24): 8613 - 8619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Um, J. K. Kwon, C.-D. Kang, M. J. Kim, D. S. Ju, J. H. Bae, D. W. Kim, B. S. Chung, and S. H. Kim Relationship between Antiapoptotic Molecules and Metastatic Potency and the Involvement of DNA-Dependent Protein Kinase in the Chemosensitization of Metastatic Human Cancer Cells by Epidermal Growth Factor Receptor Blockade J. Pharmacol. Exp. Ther., December 1, 2004; 311(3): 1062 - 1070. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Yezhelyev, G. Koehl, M. Guba, T. Brabletz, K.-W. Jauch, A. Ryan, A. Barge, T. Green, M. Fennell, and C. J. Bruns Inhibition of Src Tyrosine Kinase as Treatment for Human Pancreatic Cancer Growing Orthotopically in Nude Mice Clin. Cancer Res., December 1, 2004; 10(23): 8028 - 8036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. G. Yigitbasi, M. N. Younes, D. Doan, S. A. Jasser, B. A. Schiff, C. D. Bucana, B. N. Bekele, I. J. Fidler, and J. N. Myers Tumor Cell and Endothelial Cell Therapy of Oral Cancer by Dual Tyrosine Kinase Receptor Blockade Cancer Res., November 1, 2004; 64(21): 7977 - 7984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takada, H. M. Weiss, O. Kretz, G. Gross, and Y. Sugiyama HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154 Drug Metab. Dispos., November 1, 2004; 32(11): 1272 - 1278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. McCarty, J. Wey, O. Stoeltzing, W. Liu, F. Fan, C. Bucana, P. F. Mansfield, A. J. Ryan, and L. M. Ellis ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer Mol. Cancer Ther., September 1, 2004; 3(9): 1041 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Emanuel, R. H. Gruninger, A. Fuentes-Pesquera, P. J. Connolly, J. A. Seamon, S. Hazel, R. Tominovich, B. Hollister, C. Napier, M. R. D'Andrea, et al. A Vascular Endothelial Growth Factor Receptor-2 Kinase Inhibitor Potentiates the Activity of the Conventional Chemotherapeutic Agents Paclitaxel and Doxorubicin in Tumor Xenograft Models Mol. Pharmacol., September 1, 2004; 66(3): 635 - 647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Chen, X. Zhang, M. Li, Z. Wang, H. S. Wieand, J. R. Grandis, and D. M. Shin Simultaneously Targeting Epidermal Growth Factor Receptor Tyrosine Kinase and Cyclooxygenase-2, an Efficient Approach to Inhibition of Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., September 1, 2004; 10(17): 5930 - 5939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Lorch, J. Klessner, J. K. Park, S. Getsios, Y. L. Wu, M. S. Stack, and K. J. Green Epidermal Growth Factor Receptor Inhibition Promotes Desmosome Assembly and Strengthens Intercellular Adhesion in Squamous Cell Carcinoma Cells J. Biol. Chem., August 27, 2004; 279(35): 37191 - 37200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zingg, O. Riesterer, D. Fabbro, C. Glanzmann, S. Bodis, and M. Pruschy Differential Activation of the Phosphatidylinositol 3'-Kinase/Akt Survival Pathway by Ionizing Radiation in Tumor and Primary Endothelial Cells Cancer Res., August 1, 2004; 64(15): 5398 - 5406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Traxler, P. R. Allegrini, R. Brandt, J. Brueggen, R. Cozens, D. Fabbro, K. Grosios, H. A. Lane, P. McSheehy, J. Mestan, et al. AEE788: A Dual Family Epidermal Growth Factor Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity Cancer Res., July 15, 2004; 64(14): 4931 - 4941. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Kim, H. Uehara, S. Yazici, R. R. Langley, J. He, R. Tsan, D. Fan, J. J. Killion, and I. J. Fidler Simultaneous Blockade of Platelet-Derived Growth Factor-Receptor and Epidermal Growth Factor-Receptor Signaling and Systemic Administration of Paclitaxel as Therapy for Human Prostate Cancer Metastasis in Bone of Nude Mice Cancer Res., June 15, 2004; 64(12): 4201 - 4208. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Lev, A. Onn, V. O. Melinkova, C. Miller, V. Stone, M. Ruiz, E. C. McGary, H. N. Ananthaswamy, J. E. Price, and M. Bar-Eli Exposure of Melanoma Cells to Dacarbazine Results in Enhanced Tumor Growth and Metastasis In Vivo J. Clin. Oncol., June 1, 2004; 22(11): 2092 - 2100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wu, L. Chen, L. Cao, W. Sheng, and B. B. Yang Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and {beta}1-integrin J. Cell Sci., May 1, 2004; 117(11): 2227 - 2237. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wu, C. Parungo, G. Wu, P. M. Kang, R. J. Laham, F. W. Sellke, M. Simons, and J. Li PR39 Inhibits Apoptosis in Hypoxic Endothelial Cells: Role of Inhibitor Apoptosis Protein-2 Circulation, April 6, 2004; 109(13): 1660 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yokoi and I. J. Fidler Hypoxia Increases Resistance of Human Pancreatic Cancer Cells to Apoptosis Induced by Gemcitabine Clin. Cancer Res., April 1, 2004; 10(7): 2299 - 2306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Olszewska-Pazdrak, K. L. Ives, J. Park, C. M. Townsend Jr., and M. R. Hellmich Epidermal Growth Factor Potentiates Cholecystokinin/Gastrin Receptor-mediated Ca2+ Release by Activation of Mitogen-activated Protein Kinases J. Biol. Chem., January 16, 2004; 279(3): 1853 - 1860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ciardiello, R. Bianco, R. Caputo, R. Caputo, V. Damiano, T. Troiani, D. Melisi, F. De Vita, S. De Placido, A. R. Bianco, et al. Antitumor Activity of ZD6474, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Human Cancer Cells with Acquired Resistance to Antiepidermal Growth Factor Receptor Therapy Clin. Cancer Res., January 15, 2004; 10(2): 784 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, and D. J. McConkey The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts Mol. Cancer Ther., January 1, 2004; 3(1): 59 - 70. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. L. Janmaat and G. Giaccone Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, December 1, 2003; 8(6): 576 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Atalay, F. Cardoso, A. Awada, and M. J. Piccart Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer Ann. Onc., September 1, 2003; 14(9): 1346 - 1363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Williams, C. Pettaway, R. Song, C. Papandreou, C. Logothetis, and D. J. McConkey Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts Mol. Cancer Ther., September 1, 2003; 2(9): 835 - 843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Stoeltzing, W. Liu, N. Reinmuth, F. Fan, A. A. Parikh, C. D. Bucana, D. B. Evans, G. L. Semenza, and L. M. Ellis Regulation of Hypoxia-Inducible Factor-1{alpha}, Vascular Endothelial Growth Factor, and Angiogenesis by an Insulin-Like Growth Factor-I Receptor Autocrine Loop in Human Pancreatic Cancer Am. J. Pathol., September 1, 2003; 163(3): 1001 - 1011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. She, F. Lee, J. Chen, A. Haimovitz-Friedman, V. A. Miller, V. R. Rusch, M. G. Kris, and F. M. Sirotnak The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Selectively Potentiates Radiation Response of Human Tumors in Nude Mice, with a Marked Improvement in Therapeutic Index Clin. Cancer Res., September 1, 2003; 9(10): 3773 - 3778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Holsinger, D. D. Doan, S. A. Jasser, E. A. Swan, J. S. Greenberg, B. A. Schiff, B. N. Bekele, M. N. Younes, C. D. Bucana, I. J. Fidler, et al. Epidermal Growth Factor Receptor Blockade Potentiates Apoptosis Mediated by Paclitaxel and Leads to Prolonged Survival in a Murine Model of Oral Cancer Clin. Cancer Res., August 1, 2003; 9(8): 3183 - 3189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Garofalo, E. Naumova, L. Manenti, C. Ghilardi, G. Ghisleni, M. Caniatti, T. Colombo, J. M. Cherrington, E. Scanziani, M. I. Nicoletti, et al. The Combination of the Tyrosine Kinase Receptor Inhibitor SU6668 with Paclitaxel Affects Ascites Formation and Tumor Spread in Ovarian Carcinoma Xenografts Growing Orthotopically Clin. Cancer Res., August 1, 2003; 9(9): 3476 - 3485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mendelsohn and J. Baselga Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer J. Clin. Oncol., July 15, 2003; 21(14): 2787 - 2799. [Abstract] [Full Text] [PDF]
|
|
